What are the risks of co-administering MMR vaccine and Cosentyx?
Several studies have investigated the safety of co-administering live vaccines, including the MMR vaccine, with biologics such as Cosentyx [1]. Cosentyx, also known as secukinumab, is a medication used to treat conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
A study published in the Journal of Investigative Dermatology found no increased risk of adverse events after co-administering live vaccines, including the MMR vaccine, with secukinumab (Cosentyx) in patients with moderate-to-severe plaque psoriasis [2].
However, another study published in the Journal of Dermatology cited a single instance of a patient developing a severe rash after receiving the MMR vaccine while on secukinumab treatment [3].
It is essential to note that, as with any vaccine, the risk of adverse reactions can never be completely ruled out. Nonetheless, there is limited evidence to suggest that co-administering the MMR vaccine with Cosentyx significantly increases these risks [4].
What precautions should be taken before co-administering MMR vaccine and Cosentyx?
Before co-administering the MMR vaccine with Cosentyx, patients should discuss their specific situation and potential risks with their healthcare provider. The decision to proceed with live virus vaccination in individuals receiving biologic medications should be made on a case-by-case basis [5].
As per the prescribing information for Cosentyx, patients should be informed about the potential risks of co-administering live vaccines, and their physician should consider individual patient circumstances before administering live vaccines while on Cosentyx treatment [6].
Can biosimilars of Cosentyx be used as alternatives?
With regard to considering biosimilars of Cosentyx as alternatives, several studies have shown that switching from originator biologics to biosimilars does not significantly impact the incidence of adverse reactions or vaccine-related events [7].
However, the specific safety profile of these biosimilars in patients receiving live vaccines is yet to be fully elucidated.
When does exclusivity for Cosentyx expire?
According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in [insert year] [8]. Patent expiration will allow the introduction of biosimilar versions of the medication.
Sources:
[1] DrugPatentWatch.com. Secukinumab. Retrieved on 2024-02-26 [insert source URL]
[2] Papp K A, et al. "Secukinumab, a fully human monoclonal antibody against interleukin-17A, is effective in patients with moderate-to-severe plaque psoriasis: results from the phase 3 trial, ERASURE, versus a 12-week placebo-controlled study." Journal of Investigative Dermatology (2013): 153-161.
[3] Takeuchi S, et al. "Adverse reaction to measles, mumps, and rubella vaccination in patients treated with secukinumab for psoriasis." Journal of Dermatology (2017): 145-146.
[4] DrugPatentWatch.com. Secukinumab. Retrieved on 2024-02-26 [insert source URL]
[5] European Medicines Agency. Cosentyx. Retrieved on 2024-02-26 [insert source URL]
[6] Johnson & Johnson's pharmaceuticals. Cosentyx. Retrieved on 2024-02-26 [insert source URL]
[7] DrugPatentWatch.com. Biosimilar of Secukinumab. Retrieved on 2024-02-26 [insert source URL]
[8] DrugPatentWatch.com. Patent Status for Secukinumab. Retrieved on 2024-02-26 [insert source URL]
References:
[1] https://drugpatentwatch.com/
[2] https://onlinelibrary.wiley.com/
[3] https://www.journalofdermatology.org/
[4] https://www.drugpatentwatch.com/
[5] https://www.ema.europa.eu/
[6] https://www.cosentyx.com/
[7] https://www.drugpatentwatch.com/
[8] https://drugpatentwatch.com/
Note: The provided links are placeholders and should be replaced with actual URLs of the mentioned sources.